-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $27

Benzinga·10/13/2026 15:33:02
Listen to the news
Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $22 to $27.